Anebulo Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANEB research report →
Range $6 – $6
Price Chart
About the company
Anebulo Pharmaceuticals, Inc. , a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity.
- CEO
- Richard Anthony Cunningham
- IPO
- 2021
- Employees
- 3
- HQ
- Lakeway, TX, US
Get TickerSpark's AI analysis on ANEB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.05M
- P/E
- -2.09
- PEG
- -0.05
- P/S
- 0.00
- P/B
- 1.66
- EV/EBITDA
- -0.64
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -64.46%
- ROIC
- -81.32%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-9,223,481
- Net Income
- $-8,484,763-3.4%
- EPS
- $-0.25+21.9%
- OCF Growth
- +21.5%
- FCF Growth
- +21.5%
- 52W High
- $2.85
- 52W Low
- $0.00
- 50D MA
- $0.33
- 200D MA
- $0.57
- Beta
- -1.86
- RSI (14)
- 48
- Avg Volume
- 251
No earnings-call transcripts are available for ANEB yet.
- Free Float
- 59.2%
- Shares Outstanding
- 40.78M
- Float Shares
- 24.13M
of shares held by institutions
20 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 435.82K | ▲ 129.28K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 4, 25 | Lawler Joseph F. | other | 25,000 |
| Apr 4, 25 | Lawler Joseph F. | other | 13,236 |
| Apr 4, 25 | SHAH BIMAL R. | other | 25,000 |
| Apr 4, 25 | SHAH BIMAL R. | other | 6,618 |
| Apr 4, 25 | Cundy Kenneth C | other | 115,037 |
| Apr 4, 25 | Aryeh Jason | other | 25,000 |
| Apr 4, 25 | Aryeh Jason | other | 4,964 |
| Apr 4, 25 | Cunningham, Richard Anthony | other | 316,352 |
| Apr 4, 25 | Lin Kenneth | other | 25,000 |
| Apr 4, 25 | Lin Kenneth | other | 4,964 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANEB coverage
Recent articles, reports, and earnings notes.
No research on ANEB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANEB report →Anebulo Pharmaceuticals (ANEB) to Announce Earnings on Wednesday
defenseworld.net · Sep 16
Anebulo Pharmaceuticals (NASDAQ:ANEB) & Replimune Group (NASDAQ:REPL) Critical Comparison
defenseworld.net · Mar 12
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
businesswire.com · Feb 12
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
businesswire.com · Feb 6
Anebulo Pharmaceuticals (NASDAQ:ANEB) Trading Down 13.6% – What’s Next?
defenseworld.net · Feb 6
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Down 13.6% – What’s Next?
defenseworld.net · Feb 6
Anebulo Pharmaceuticals Announces Final Results of Tender Offer
businesswire.com · Jan 29
Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer
businesswire.com · Jan 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.